Interleukin 2 high-affinity receptor expression requires two distinct binding proteins - PubMed (original) (raw)
Interleukin 2 high-affinity receptor expression requires two distinct binding proteins
K Teshigawara et al. J Exp Med. 1987.
Abstract
A cell line established from a patient with acute lymphoblastic leukemia was found to express IL-2 binding sites with a novel, intermediate affinity compared with the characteristic high-affinity IL-2-receptors and low-affinity IL-2 binding sites described previously. Clones were isolated from this cell line that displayed solely this new IL-2-binding protein, and were found to be unreactive with anti-Tac, the mAb that competes with IL-2 for binding. Moreover, these same cloned cells did not express mRNA detectable by hybridization with radiolabeled cDNA encoding the Tac protein. In contrast, the original cell line and similar clones expressed low levels of Tac mRNA and cell surface Tac antigen, both of which could be augmented by exposure to medium conditioned by adult T leukemia cell lines. Particularly noteworthy, induction of Tac antigen expression was paralleled by an increase in the number of high-affinity IL-2-R detectable. Since the expression of the Tac antigen protein by itself makes only for low-affinity IL-2 binding, these data prompted a reevaluation of the structural composition of high-affinity IL-2-R. Analysis of the IL-2-binding proteins expressed by leukemic cell lines lacking high-affinity receptors revealed only a single protein, larger than the Tac antigen protein (Mr = 75,000 vs. 55,000). In contrast, clones induced to express high-affinity receptors had clearly both of these IL-2-binding proteins. Moreover, when IL-2 binding to normal T cells was performed under conditions that favored the proportion of high-affinity receptors occupied, two distinct proteins identical to those already identified on the leukemic cells could be crosslinked covalently to radiolabeled IL-2. The interpretations derived from these varied, assembled data, point to two IL-2-binding proteins, both of which are required for high-affinity IL-2 binding.
Similar articles
- A second human interleukin-2 binding protein that may be a component of high-affinity interleukin-2 receptors.
Dukovich M, Wano Y, Le thi Bich Thuy, Katz P, Cullen BR, Kehrl JH, Greene WC. Dukovich M, et al. Nature. 1987 Jun 11-17;327(6122):518-22. doi: 10.1038/327518a0. Nature. 1987. PMID: 3108674 - Abnormal expression of interleukin-2 receptor (Tac antigen) in adult T-cell leukemia.
Uchiyama T, Wano Y, Tsudo M, Umadome H, Hori T, Tamori S, Uchino H, Yodoi J, Maeda M, Kobayashi N, et al. Uchiyama T, et al. Princess Takamatsu Symp. 1984;15:253-8. Princess Takamatsu Symp. 1984. PMID: 6100643 - Expression of interleukin 2 receptors on activated human B cells.
Waldmann TA, Goldman CK, Robb RJ, Depper JM, Leonard WJ, Sharrow SO, Bongiovanni KF, Korsmeyer SJ, Greene WC. Waldmann TA, et al. J Exp Med. 1984 Nov 1;160(5):1450-66. doi: 10.1084/jem.160.5.1450. J Exp Med. 1984. PMID: 6092511 Free PMC article. - The role of the multichain IL-2 receptor complex in the control of normal and malignant T-cell proliferation.
Waldmann TA. Waldmann TA. Environ Health Perspect. 1987 Nov;75:11-5. doi: 10.1289/ehp.877511. Environ Health Perspect. 1987. PMID: 2891501 Free PMC article. Review. - The multichain interleukin-2 receptor: a target for immunotherapy of patients receiving allografts.
Waldmann TA, Goldman CK. Waldmann TA, et al. Am J Kidney Dis. 1989 Nov;14(5 Suppl 2):45-53. Am J Kidney Dis. 1989. PMID: 2683757 Review.
Cited by
- The T-Cell Growth Factor Interleukin-2, Which Is Occasionally Targeted by Autoantibodies, Qualifies as Drug for the Treatment of Allergy, Autoimmunity, and Cancer: Collegium Internationale Allergologicum (CIA) Update 2024.
Sehgal ANA, Tauber PA, Stieger RB, Kratzer B, Pickl WF. Sehgal ANA, et al. Int Arch Allergy Immunol. 2024;185(3):286-300. doi: 10.1159/000533677. Epub 2023 Dec 12. Int Arch Allergy Immunol. 2024. PMID: 38086339 Free PMC article. Review. - Oscillatory IL-2 stimulus reveals pertinent signaling timescales of T cell responsiveness.
Kippner LE, Kemp ML. Kippner LE, et al. PLoS One. 2018 Sep 18;13(9):e0203759. doi: 10.1371/journal.pone.0203759. eCollection 2018. PLoS One. 2018. PMID: 30226854 Free PMC article. - The Common Cytokine Receptor γ Chain Family of Cytokines.
Lin JX, Leonard WJ. Lin JX, et al. Cold Spring Harb Perspect Biol. 2018 Sep 4;10(9):a028449. doi: 10.1101/cshperspect.a028449. Cold Spring Harb Perspect Biol. 2018. PMID: 29038115 Free PMC article. Review. - Interleukin-2 Functions in Anaplastic Large Cell Lymphoma Cells through Augmentation of Extracellular Signal-Regulated Kinases 1/2 Activation.
Ito M, Zhao N, Zeng Z, Zhou X, Chang CC, Zu Y. Ito M, et al. Int J Biomed Sci. 2011 Sep;7(3):181-90. Int J Biomed Sci. 2011. PMID: 23675235 Free PMC article. - Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity.
Goudy K, Aydin D, Barzaghi F, Gambineri E, Vignoli M, Ciullini Mannurita S, Doglioni C, Ponzoni M, Cicalese MP, Assanelli A, Tommasini A, Brigida I, Dellepiane RM, Martino S, Olek S, Aiuti A, Ciceri F, Roncarolo MG, Bacchetta R. Goudy K, et al. Clin Immunol. 2013 Mar;146(3):248-61. doi: 10.1016/j.clim.2013.01.004. Epub 2013 Jan 24. Clin Immunol. 2013. PMID: 23416241 Free PMC article.
References
- Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 - PubMed
- Proc Natl Acad Sci U S A. 1981 Jan;78(1):616-20 - PubMed
- J Exp Med. 1981 Nov 1;154(5):1455-74 - PubMed
- Nature. 1982 Nov 18;300(5889):267-9 - PubMed
- J Biol Chem. 1983 Dec 10;258(23):14675-81 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials